



Section #11  
J 1.10.02

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Albert P. Tseng, et al.

**Examiner:** Yaen, Christopher H.

**Serial No.:** 09/831,744

**Art Unit:** 1642

**Filed:** January 25, 2001

**Docket:** 13030

**For:** PHOSPHOLIPASE INHIBITORS  
FOR THE TREATMENT OF CANCER

**Dated:** January 3, 2003

Assistant Commissioner for Patents  
Washington, DC 20231

RECEIVED  
JAN 07 2003  
TECH CENTER 1600/2900

**RESPONSE PURSUANT TO 37 C.F.R. §§1.111 AND 1.143**

Sir:

In response to the Office Action dated July 3, 2002, setting forth a requirement for species election, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, Applicants provisionally elect, with traverse, the species of SEQ ID NO: 1, which sets forth the amino acid sequence of the *N. scutatus* Phospholipase A<sub>2</sub> inhibitor (or "NSI")  $\alpha$  chain.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on January 3, 2003.

Dated: January 3, 2003

  
Michelle Mustafa